Over the past three decades, the landscape of non-small cell lung cancer (NSCLC) treatment has been profoundly transformed by the advent and continued evolution of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). These targeted therapies have revolutionized clinical outcomes for patients harboring EGFR-sensitive mutations, ushering in an era of precision medicine that has markedly extended progression-free survival (PFS) and overall survival (OS). With an expanding pharmacological arsenal comprising gefitinib, erlotinib, icotinib, osimertinib, and numerous other agents, clinicians now face both exciting opportunities and formidable challenges as they optimize treatment regimens for diverse mutational profiles.
First-line monotherapy with EGFR-TKIs typically yields a median PFS ranging from 9.6 to 22.1 months and OS between 16.6 and 38.6 months, underscoring the substantial efficacy of these agents. Recently, combination therapies have demonstrated even greater promise. The pivotal FLAURA2 study established that osimertinib combined with chemotherapy significantly improves PFS to 29.4 months compared to 19.9 months with monotherapy, with a hazard ratio (HR) of 0.62 and a p-value less than 0.001. This breakthrough led to regulatory approvals by both the U.S. FDA and China’s NMPA in early 2024, marking a milestone in personalized oncology.
In parallel, the MARIPOSA trial highlighted the efficacy of combining lazertinib, a third-generation irreversible EGFR-TKI, with amivantamab, a bispecific antibody targeting EGFR and MET. This combination extended PFS to 23.7 months versus 16.6 months for control, with an HR of 0.70, rapidly gaining FDA approval later in 2024. These clinical advances underscore a shifting paradigm toward multipronged therapeutic strategies that target both the primary oncogenic driver and associated resistance pathways.
Uncommon EGFR mutations such as exon 20 insertions, G719X, L861Q, and S768I have historically posed significant clinical challenges due to their intrinsic resistance to first-generation TKIs. However, recent investigations have yielded promising new avenues. The WU-KONG6 study revealed that sunvozertinib exhibits an objective response rate (ORR) of 61% in post-line settings and an exceptional 73.1% in the first-line context for exon 20 insertion mutations, culminating in NMPA approval in August 2023. Complementing these findings, the PAPILLON trial demonstrated that the combination of amivantamab with chemotherapy dramatically prolonged PFS to 11.4 months compared to 6.7 months in controls, achieving FDA clearance in March 2024.
For other less common mutations such as G719X, L861Q, and S768I, first-generation EGFR-TKIs show limited activity. Instead, second- and third-generation inhibitors have shown greater efficacy. Afatinib received FDA approval in 2018 for these mutants, while osimertinib has demonstrated an ORR between 50% and 55%. Novel agents like mefatinib have achieved remarkable ORRs reaching 85.7%, earning breakthrough therapy status by the NMPA in 2023. Ongoing clinical trials investigating furmonertinib and sutetinib continue to expand the therapeutic landscape for these mutation subtypes.
Perioperative application of EGFR-TKIs is another frontier redefining standard NSCLC management, particularly in early-stage disease. The EVIDENCE study revealed that adjuvant icotinib more than doubled disease-free survival (DFS) to 47.0 months versus 22.1 months, affirming its regulatory approval for stage II-IIIA adjuvant treatment in China in 2021. Similarly, the landmark ADAURA trial demonstrated that adjuvant osimertinib substantially prolongs DFS to 65.8 months compared to 21.9 months, prompting FDA approval for stages IB-IIIA in 2020. Exploratory trials investigating neoadjuvant use of EGFR-TKIs further suggest potential benefits, although phase 3 results are awaited.
Despite these therapeutic triumphs, resistance to EGFR-TKIs remains an inevitable and complex clinical hurdle. Resistance mechanisms can be broadly divided into primary, typified by innate insensitivity such as exon 20 insertion mutations, and secondary, which develop during treatment. Secondary resistance is further categorized into on-target alterations, including EGFR amplification and mutations like T790M and C797S, and off-target mechanisms such as MET, HER2, and FGFR amplifications, activation of downstream signaling cascades (e.g., RAS–MAPK, PI3K/AKT/mTOR), epithelial-mesenchymal transition (EMT), and small cell lung cancer (SCLC) histologic transformation.
Post-resistance management strategies aim to overcome this array of molecular evasions. First- and second-generation EGFR-TKIs commonly lose efficacy within 9.2 to 14.7 months due largely to the emergence of the T790M mutation. Third-generation agents have extended this timeline to 18.9 to 22.1 months, yet resistance driven by the C797S mutation subsequently undermines therapeutic durability. To address this, several fourth-generation TKIs—including BBT-176 and BLU-945—are undergoing clinical development, designed to re-target resistant mutant EGFR conformations.
Moreover, targeted combination regimens addressing non-EGFR resistance pathways have shown clinical benefit. For example, the ORIENT-31 trial demonstrated that adding sintilimab, an anti-PD-1 antibody, and bevacizumab, an anti-VEGF agent, to chemotherapy improved PFS from 4.3 to 6.9 months with an HR of 0.46 and highly significant p-value (0.0001). Likewise, the HARMONi-A study reported that evoralimab combined with chemotherapy enhanced PFS from 4.80 to 7.06 months, achieving NMPA approvals in 2023 and 2024, respectively.
In summary, the continual evolution and optimization of EGFR-TKIs have fundamentally transformed the treatment landscape for NSCLC patients with EGFR mutations, substantially improving survival outcomes and quality of life. However, overcoming resistance mechanisms, fine-tuning combination therapy regimens, and determining optimal treatment durations remain critical areas for ongoing research. The synthesis of unprecedented clinical trial data and emergent molecular insights promises to underpin increasingly precise and individualized therapeutic strategies in future neuro-oncology paradigms.
This comprehensive review of advances in EGFR-TKI therapies was published in the April 2026 issue of the Chinese Medical Journal, reinforcing the importance of integrating cutting-edge molecular and clinical findings to reshape NSCLC management over the next decades.
Subject of Research: Not applicable
Article Title: Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026)
News Publication Date: 5-Apr-2026
References: DOI: 10.1097/CM9.0000000000004016
Image Credits: Prof. Yuankai Shi from National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Keywords: Cancer, Lung cancer, Oncology, Drug resistance, Clinical trials, Pharmacology, Molecular biology, Genetics
Tags: advancements in tyrosine kinase inhibitorsclinical trials FLAURA2 and MARIPOSAEGFR-TKIs in non-small cell lung cancerFDA and NMPA regulatory approvalsfirst-line treatment for EGFR-mutant NSCLCosimertinib combination chemotherapyovercoming drug resistance in lung cancerpersonalized oncology therapiesprecision medicine in lung cancerprogression-free survival in NSCLCresistance mechanisms to EGFR inhibitorstargeted therapy for EGFR mutations
